IAI CONFERENCE: The effect of loss-of-function allele (CYP2C19*3) with Clopidogrel efficacy in coronary heart disease patients
DOI:
https://doi.org/10.46542/pe.2021.212.178183Keywords:
Antiplatelet, Clopidogrel, Coronary heart disease, CYP2C19*3 polymorphismsAbstract
Introduction: Clopidogrel is the most widely prescribed antiplatelet for patients with coronary heart disease (CHD) who cannot take aspirin. Despite its effectiveness, Clopidogrel has several side effects caused by its metabolite. Clopidogrel resistance has been identified in some patients, and patient factors such as genetic polymorphisms in CYP2C19 may play a role in this resistance. The researchers wanted to look at CYP2C19*3 polymorphisms and platelet aggregation in CHD patients who were taking clopidogrel.
Methods: This research used a cross-sectional design. The research enrolled CHD patients at a local hospital's cardiology unit with certain inclusion and exclusion requirements. In the clinical laboratory, CYP2C19*3 polymorphisms was investigated using polymerase chain reaction (PCR), and platelet aggregation will be measured using light transmission aggregometry (LTA).
Results: This research enlisted the participation of 53 patients. The majority of the patients (68%) were men, with the highest age group being 60-69 years old. The most common comorbid disorder was hypertension. The result of CYP2C19*3 polymorphisms as follows: GA (75%), AA (21%), and GG (4%). Hypo-aggregation (89%) and normal-aggregation (89%) are seen in the majority of patients (11%). The authors were unable to locate the patient who had hyper-aggregation.
Conclusion: According to descriptive research, CYP2C19*3 polymorphisms caused hypo-aggregation in more patients than normal aggregation in this study.
References
Adithan, C., Gerard, N., Vasu, S., Rosemary, J., Shashindran, C.H., Krishnamoorthy, R. (2003). Allele and genotype frequency of CYP2C19 in a Tamilian population. Journal of Clinical Pharmacology, 56, 331-33. https://doi.org/10.1046/j.1365-2125.2003.01883.x
Aradi, D., Storey, R.F., Kom_ocsi, A., Trenk, D., Gulba, D., Kiss, R.G., Husted, S., Bonello, L., Sibbing, D., Collet, J.P., Huber, K. (2014). Working group on thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 35, 209-215. https://doi.org/10.1093/eurheartj/eht375
Brown, S.A., & Pereira, N. (2018). Pharmacogenomic Impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. Journal of personalised medicine, 8(1), 8. https://doi.org/10.3390/jpm8010008
CAPRIE Steering Committee. (1996). A randomised, blinded, trial of Clopidogrel versus Aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329-1339. https://doi.org/10.1016/s0140-6736(96)09457-3
Chan, Mark, Y. (2012). Clopidogrel Pharmacogenetics of east, south and other Asian populations. European Heart Journal Supplements, Volume 14, A41-A42. https://doi.org/10.1093/eurheartj/sur035
Cacabelos, R. (2012). The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders. Metabolomics 2, e119. https://doi.org/10.4172/2153-0769.1000e119
Department Kesehatan. (2014). Riset Kesehatan Dasar.
Favaloro, E.J. (2017). Clinical utility of closure times using the platelet function analyser-100/200. American journal of hematology, 92(4), 398–404. https://doi.org/10.1002/ajh.24620
Harrison, P. (2000). Progress in the assessment of platelet function. British Journal of Haematology, 111, 733-44. https://doi.org/10.1111/j.1365-2141.2000.02269.x
Jeong, Y., Tantry, U.S., Kim, I., Koh, J., Kwon, T.J., Park, Y., Hwang, S., Bliden, K.P., Kwak, C.H., Hwang, J., Gurbel, P.A. (2011). Effect of CYP2C19*2 and CYP2C19*3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with Clopidogrel and Aspirin. Circulation Cardiovascular Interventions, 4, 585-594. https://doi.org/10.1161/CIRCINTERVENTIONS.111.962555
Johnson, J.A., Gong, L., Whirl-Carrillo, M., Gage, B.F., Scott, S.A., Stein C.M., Anderson, J.L., Kimmel, S.E., Lee, M.T.M., Pirmohamed, M., Wadelius, M., Klein, T.E., Altman, R.B. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical Pharmacology & Therapeutics, 90, 625-29. https://doi.org/10.1038/clpt.2011.185
Kim, I.S., Choi, B.R., Jeong, Y.H., Kwaks, C.H., Kim, S. (2009). The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. Journal of Thrombosis and Haemostasis, 7, 897-899. https://doi.org/10.1111/j.1538-7836.2009.03319.x
Kitzmiller, J.P., Groen, D.K., Phelps, M.A., Sadee, W. (2011). Pharmacgenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleveland Clinic Journal of Medicine, 78, 243-257. https://doi.org/10.3949/ccjm.78a.10145
Koltai, K., Kesmarky, G., Feher, G., Tibold, A., & Toth, K. (2017). Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. International journal of molecular sciences, 18(8), 1803. https://doi.org/10.3390/ijms18081803
Lenk, E., Spannagl, M. (2014). Platelet Function Testing-Guided Antiplatelet Therapy. Electronic Journal of International Federation of Clinical Chemistry and Laboratory Medicine, 24(3): 90-96
Liau,Y., Muliaty, D. (2014). The Pharmacogenetics of Cytochrome P450 2C19 – enzymes Effects on Clopidogrel and Proton Pump Inhibitors. The Indonesia Biomedical Journal, 6(1), 33-44
Lyon, E., Foster, J.G., Palomaki, G.E., Pratt, V.M., Reynolds, K., Sabato, M.F., Scott, S.A., Vitazka, P. (2012). Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genetics in Medicine, 14, 990-1000. https://doi.org/10.1038/gim.2012.108
Michelson, A.D. (2004).Platelet function testing in cardiovascular diseases. Circulation, 110(19), e489–e493. https://doi.org/10.1161/01.CIR.0000147228.29325.F9
Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Yildirir, A. (2013). 2013 ESC guidelines on the management of stable coronary artery disease - addenda. European Heart Journal, 34(38), 2949–3003. https://doi.org/10.1093/eurheartj/eht296
Rand, M. L., Leung, R., & Packham, M. A. (2003). Platelet function assays. Transfusion and apheresis science. Official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis, 28(3), 307–317. https://doi.org/10.1016/S1473-0502(03)00050-8
Remijin, J.A., Wu, Y., Jeninga, E.H., Ijsseldijk, M.J.W., Willigen, G.V., Groot, P.G., Sixma, J.J., Nurden, A.T., Nurden, P. (2002). Role of ADP Receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 686-691. https://doi.org/10.1161/01.ATV.0000012805.49079.23
Speed, W.C., Kang, S.P., Tuck, D.P., Harris, L.N., Kidd, K.K. (2009). Global variation in CYP2C8-CYP2C9 functional haplotypes. The Pharmacogenomics Journal, 9, 283–290. https://doi.org/10.1038/tpj.2009.10
Strom, C.M., Goos, D., Crossley, B., Zhang, K., Buller-Burkle, A., Jarvis, M., Quan, F., Peng, M., Sun, W. (2012). Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genetics in Medicine, 14, 95- 100. https://doi.org/10.1038/gim.0b013e3182329870
Wei, Y.Q., Wang, D.G., Yang, H., Cao, H. (2015). Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PLOS ONE, 10(7), e0132561. https://doi.org/10.1371/journal.pone.0132561
World Health Organisation, World Heart Federation, World Stroke Organization. (2012). Global Atlas on Cardiovascular disease prevention and control. 155. https://doi.org/NLM classification: WG 120
Yamamoto, K., Hokimoto, S., Chitose, T., Morita, K., Ono, T., Kaikita, K., et al. (2011). Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. Journal of Cardiology, 57, 194-201. https://doi.org/10.1016/j.jjcc.2010.10.007
Yin, T., Miyata, T. Pharmacogenomics of clopidogrel: Evidence and perspectives. Thrombosis Research. 2011, 128(4), 307–16. https://doi.org/10.1016/j.thromres.2011.04.010
Zhu, W.Y., Zhao, T., Xiong, X., Li, J., Wang, L., Zhu, Y., et al. 2016. Association of CYP2C19 polymorphisms with the clinical efficacy of clopidogrel therapy in patients undergoing carotid artery stenting in Asia. Scientific reports. 6:25478. https://doi.org/10.1038/srep25478
